Prevalence of blood stream infections and associated factors among febrile neutropenic cancer patients on chemotherapy at Ocean Road Cancer Institute, Tanzania
- PMID: 37730617
- PMCID: PMC10510178
- DOI: 10.1186/s13027-023-00533-8
Prevalence of blood stream infections and associated factors among febrile neutropenic cancer patients on chemotherapy at Ocean Road Cancer Institute, Tanzania
Abstract
Background: Febrile Neutropenia (FN) caused by bacteria in cancer patients is associated with poor prognosis. The aim of this study was to determine the prevalence of FN and associated factors among cancer patients on chemotherapy at Ocean Road Cancer Institute (ORCI), Tanzania.
Methods: A cross-sectional study was conducted from June to September 2019. Study participants were conveniently recruited. A desk review of participants medical records was performed. Standard microbiological procedures used to culture and identify the bacterial isolates from the positive blood cultures of participants that presented with FN. Kirby-Bauer disc diffusion was used to perform the antibiotics susceptibility testing. SPSS version 20.0 and MS Excel were used in data entry and analysis. Chi-Square was used as a measure of association between various factors and neutropenia. P-value less than 0.05 was considered statistically significant.
Results: A total 213 participants were enrolled. Of these 76.1% were female. Most of the participants came from the Coast region. Majority of participants presented with breast Cancer (36.2%) and GIT (20.2%). The prevalence of FN and bacteremia was 5.6% and 35.3% respectively. Staphylococcus Aureus (60%) and Coagulase-Negative Staphylococci (40%) were the main isolates. Of the 6 isolates tested most were resistant to Co-Trimoxazole 4/6 (66.7%) and Doxycycline 3/6 (50%). FN was positively associated with chemotherapy regimen (P = 0.0001), platelets count (P = 0.0001) and use of G-CSF (P = 0.0001).
Conclusion: The prevalence of FN among the cancer patients on chemotherapy in Tanzania is low but associated with drug-resistant bacteria.
Keywords: BSIs; Bacteremia; Cancer; Chemotherapy; FN; Febrile Neutropenia; ORCI; Susceptibility; Tanzania.
© 2023. BioMed Central Ltd., part of Springer Nature.
Conflict of interest statement
The authors declare that they have no competing interests in this study.
Figures
Similar articles
-
Clinical implications of icaA and icaD genes in coagulase negative staphylococci and Staphylococcus aureus bacteremia in febrile neutropenic pediatric cancer patients.Pediatr Blood Cancer. 2009 Jul;52(7):824-8. doi: 10.1002/pbc.21964. Pediatr Blood Cancer. 2009. PMID: 19214976
-
Bacterial profile and antimicrobial susceptibility patterns in cancer patients.PLoS One. 2022 Apr 15;17(4):e0266919. doi: 10.1371/journal.pone.0266919. eCollection 2022. PLoS One. 2022. PMID: 35427384 Free PMC article.
-
Pediatric Febrile Neutropenia: Change in Etiology of Bacteremia, Empiric Choice of Therapy and Clinical Outcomes.J Pediatr Hematol Oncol. 2020 Aug;42(6):e445-e451. doi: 10.1097/MPH.0000000000001814. J Pediatr Hematol Oncol. 2020. PMID: 32404688
-
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.Eur J Cancer. 2011 Jan;47(1):8-32. doi: 10.1016/j.ejca.2010.10.013. Epub 2010 Nov 20. Eur J Cancer. 2011. PMID: 21095116
-
[Prevention and treatment of febrile neutropenia].Tumori. 1997;83(2 Suppl):S15-9. Tumori. 1997. PMID: 9235724 Review. Italian.
Cited by
-
Survivorship Struggles: Navigating Etiologies and Clinical Parameters of Febrile Neutropenia During Induction Chemotherapy in Acute Leukemia Patients.Cureus. 2024 Feb 26;16(2):e54935. doi: 10.7759/cureus.54935. eCollection 2024 Feb. Cureus. 2024. PMID: 38544593 Free PMC article.
-
Etiology, Risk Factors, and Outcomes of Bacteremia in Patients With Hematologic Malignancies and Febrile Neutropenia in Uganda.Open Forum Infect Dis. 2024 Nov 16;11(12):ofae682. doi: 10.1093/ofid/ofae682. eCollection 2024 Dec. Open Forum Infect Dis. 2024. PMID: 39660025 Free PMC article.
References
-
- Rasmy A, Amal A FS and SW. Febrile Neutropenia in Cancer Patient: Epidemiology, Microbiology, Pathophysiology and Management. J Cancer Prev Curr Res. 2016;5(3). http://medcraveonline.com/JCPCR/JCPCR-05-00165.php
-
- Tohamy ST, Aboshanab KM, El-Mahallawy HA, El-Ansary MR, Afifi SS. Prevalence of multidrug-resistant Gram-negative pathogens isolated from febrile neutropenic cancer patients with bloodstream infections in Egypt and new synergistic antibiotic combinations. Infect Drug Resist. 2018;11:791–803. doi: 10.2147/IDR.S163293. - DOI - PMC - PubMed
-
- Carmona-Bayonas A, Jiménez-Fonseca P, Echaburu JV, Antonio M, Font C, Biosca M, et al. Prediction of serious complications in patients with seemingly stable febrile neutropenia: Validation of the clinical index of stable febrile neutropenia in a prospective cohort of patients from the FINITE study. J Clin Oncol. 2015;33(5):465–471. doi: 10.1200/JCO.2014.57.2347. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous